APA (7th ed.) Citation

Hofheinz, R., Merx, K., Haag, G. M., Springfeld, C., Ettrich, T., Borchert, K., . . . Al-Batran, S. (2022). FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: A randomized phase II trial of the AIO EGA study group. Journal of clinical oncology, 40(32), . https://doi.org/10.1200/JCO.22.00380

Chicago Style (17th ed.) Citation

Hofheinz, Ralf-Dieter, et al. "FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group." Journal of Clinical Oncology 40, no. 32 (2022). https://doi.org/10.1200/JCO.22.00380.

MLA (9th ed.) Citation

Hofheinz, Ralf-Dieter, et al. "FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group." Journal of Clinical Oncology, vol. 40, no. 32, 2022, https://doi.org/10.1200/JCO.22.00380.